呼出给药系统氟替卡松治疗伴或不伴鼻息肉的慢性鼻窦炎疗效
本文为ReOpen临床试验的事后分析,纳入伴鼻息肉(n=206)或不伴鼻息肉(n=341)的慢性鼻窦炎患者,随机接受EDS-FLU 186 μg、372 μg或安慰剂治疗24周。结果显示EDS-FLU在症状、嗅觉、鼻窦CT浑浊、急性加重及生活质量方面均优于安慰剂,且伴与不伴鼻息肉患者疗效相似。
要点
- EDS-FLU改善慢性鼻窦炎的主观和客观指标,不受鼻息肉状态影响。
- 伴与不伴鼻息肉患者的疗效交互作用无显著差异。
- 近期使用标准鼻喷激素仍有症状者,EDS-FLU仍可改善症状和SNOT-22。
核心结论
- EDS-FLU改善慢性鼻窦炎的主观和客观指标,无论是否伴鼻息肉。
研究设计与样本
- 多国、多中心、随机、EDS-安慰剂对照研究。
- 伴鼻息肉患者206例,不伴鼻息肉患者341例,按1:1:1随机分配至EDS-FLU 186 μg、372 μg或安慰剂,每鼻孔每日两次喷1或2喷,持续24周。
主要发现
- 伴和不伴鼻息肉患者中,EDS-FLU相比安慰剂在症状、嗅觉识别测试、鼻窦CT浑浊、急性加重频率、SNOT-22和PGIC方面均显著改善。
- 近期使用标准鼻喷激素仍有症状者,EDS-FLU对复合症状评分和SNOT-22的改善一致。
- 治疗与亚组交互效应表明,伴和不伴鼻息肉患者的EDS-FLU疗效幅度相似。
关键数值与推荐
- EDS-FLU剂量为186 μg或372 μg,每鼻孔每日两次喷1或2喷,持续24周。
- 主要终点包括复合症状评分、嗅觉识别测试、鼻窦CT浑浊、急性加重频率、SNOT-22和PGIC。
临床怎么用
- 对于伴或不伴鼻息肉的慢性鼻窦炎患者,可考虑使用EDS-FLU改善症状和客观指标。
- 近期标准鼻喷激素治疗效果不佳者,EDS-FLU仍可能带来症状和SNOT-22改善。
局限性
- 本文为事后分析,证据等级受限于原研究设计。
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether treatment responses to the exhalation delivery system with fluticasone (EDS-FLU; XHANCE®) differ between patients with CRS with nasal polyps (CRSwNP) and patients without nasal polyps (CRSsNP). STUDY DESIGN: Post hoc analysis of the ReOpen clinical trials conducted between November 2018 and November 2021 for a 24-week duration. SETTING: Multinational, multicenter, randomized, EDS-placebo-controlled studies. METHODS: Data were pooled from the randomized trials in which patients with CRSwNP (n = 206) or CRSsNP (n = 341) were randomly assigned (1:1:1) to EDS-FLU 186 μg, 372 μg, or EDS-placebo, 1 or 2 sprays twice daily per nostril for 24 weeks. Endpoints included composite symptom score, Smell Identification Test (SIT), sinus opacification on computed tomography (CT) scan, frequency of acute exacerbations of CRS, 22-Item Sino-Nasal Outcome Test (SNOT-22), and Patient Global Impression of Change (PGIC). RESULTS: Patients with CRSwNP and CRSsNP reported substantially greater benefits with EDS-FLU versus EDS-placebo on symptoms, SIT, sinus opacification on CT scan, incidence of acute exacerbations of CRS, and quality-of-life outcomes (SNOT-22 and PGIC). Composite symptom score and SNOT-22 improvements were consistent in the subgroup of patients entering the trial reporting symptoms despite recent standard-delivery nasal steroid spray use. Treatment-by-subgroup interaction effects indicated similar magnitude EDS-FLU treatment effect for patients with CRSwNP and patients with CRSsNP. CONCLUSION: EDS-FLU improved subjective and objective measures of CRS irrespective of nasal polyp status. TRIAL REGISTRATION: Title: Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps; ID: NCT03781804 and NCT03960580, Clinicaltrials.gov.
引用
- Schlosser RJ, Adappa ND, Chandra RK, et al. Efficacy of Exhalation Delivery System With Fluticasone in Chronic Rhinosinusitis With Versus Without Polyps. Otolaryngol Head Neck Surg. 2026. PMID: 42647052. doi:10.1002/ohn.70406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。